相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase IIIb OPINION interim analysis.
Andres Poveda et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial
Jonathan A Ledermann et al.
LANCET ONCOLOGY (2020)
Management of Adverse Events During Rucaparib Treatment for Relapsed Ovarian Cancer: A Review of Published Studies and Practical Guidance
Domenica Lorusso et al.
TARGETED ONCOLOGY (2020)
The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma
Nicoletta Colombo et al.
GYNECOLOGIC ONCOLOGY (2020)
Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma
Amit M. Oza et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
N. Colombo et al.
ANNALS OF ONCOLOGY (2019)
Advances in the Management of Platinum-Sensitive Relapsed Ovarian Cancer
Sara Bouberhan et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
1001PEffect of response to last platinum-based chemotherapy in patients (pts) with platinum-sensitive, recurrent ovarian carcinoma in the phase III study ARIEL3 of rucaparib maintenance treatment
J A Ledermann et al.
ANNALS OF ONCOLOGY (2019)
Maintenance treatment of recurrent ovarian cancer: Is it ready for prime time?
Paul DiSilvestro et al.
CANCER TREATMENT REVIEWS (2018)
Evaluation of rucaparib in platinum-sensitive recurrent ovarian carcinoma (rOC) in patients (pts) with or without residual bulky disease at baseline in the ARIEL3 study
Carol Aghajanian et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman et al.
LANCET (2017)
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Eric Pujade-Lauraine et al.
LANCET ONCOLOGY (2017)
A phase 2, randomized, double-blind, placebo-controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study
B. J. Monk et al.
ANNALS OF ONCOLOGY (2017)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
M. R. Mirza et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Maintenance chemotherapy in the management of epithelial ovarian cancer
Maurie Markman
CANCER AND METASTASIS REVIEWS (2015)
Optimising the treatment of the partially platinum-sensitive relapsed ovarian cancer patient
Nicoletta Colombo
EJC SUPPLEMENTS (2015)
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
Eric Pujade-Lauraine et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy
L. C. Hanker et al.
ANNALS OF ONCOLOGY (2012)
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Jonathan Ledermann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Clinical Trials in Recurrent Ovarian Cancer
Michael Friedlander et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2011)
Health-related quality of life in ovarian cancer patients and its impact on clinical management
Dana M. Chase et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2011)
分享论文
